Business Description
Skye Bioscience Inc
NAICS : 325412
SIC : 2834
ISIN : US64046J1007
Share Class Description:
SKYE: Ordinary SharesDescription
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 352.95 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.1 | |||||
| 3-Year EPS without NRI Growth Rate | 28.1 | |||||
| 3-Year FCF Growth Rate | 32.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 8.04 | |||||
| 9-Day RSI | 16.94 | |||||
| 14-Day RSI | 23.77 | |||||
| 6-1 Month Momentum % | -50.95 | |||||
| 12-1 Month Momentum % | 39.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.19 | |||||
| Quick Ratio | 14.19 | |||||
| Cash Ratio | 11.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -120.5 | |||||
| Shareholder Yield % | -110.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -46.77 | |||||
| ROA % | -36.47 | |||||
| ROIC % | -236.31 | |||||
| ROC (Joel Greenblatt) % | -704.96 | |||||
| ROCE % | -43.1 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.02 | |||||
| Price-to-Tangible-Book | 1.02 | |||||
| EV-to-EBIT | -0.64 | |||||
| EV-to-EBITDA | -0.65 | |||||
| EV-to-FCF | -0.56 | |||||
| Price-to-Net-Current-Asset-Value | 1.05 | |||||
| Price-to-Net-Cash | 1.26 | |||||
| Earnings Yield (Greenblatt) % | -156.25 | |||||
| FCF Yield % | -29.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SKYE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Skye Bioscience Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.838 | ||
| Beta | 2.7 | ||
| Volatility % | 286.32 | ||
| 14-Day RSI | 23.77 | ||
| 14-Day ATR ($) | 0.375964 | ||
| 20-Day SMA ($) | 3.5535 | ||
| 12-1 Month Momentum % | 39.19 | ||
| 52-Week Range ($) | 2.25 - 19.4099 | ||
| Shares Outstanding (Mil) | 30.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Skye Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Skye Bioscience Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Skye Bioscience Inc Frequently Asked Questions
What is Skye Bioscience Inc(SKYE)'s stock price today?
The current price of SKYE is $2.55. The 52 week high of SKYE is $19.41 and 52 week low is $2.25.
When is next earnings date of Skye Bioscience Inc(SKYE)?
The next earnings date of Skye Bioscience Inc(SKYE) is 2025-02-07 Est..
Does Skye Bioscience Inc(SKYE) pay dividends? If so, how much?
Skye Bioscience Inc(SKYE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers